Drugs / SITOCABNAGENE LOXIVELEUCEL
SITOCABNAGENE LOXIVELEUCEL
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT06377228 | Jun 2025 → Sep 2030 | lupus nephritis, systemic sclerosis | Takeda | Withdrawn | No outcome recorded Stop: Business |
| Phase 21 trial | ||||||
| Phase 2 | NCT05020015 | Nov 2021 → Jun 2024 overdue | B-cell non-Hodgkin lymphoma | Takeda | Active not recruiting | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SITOCABNAGENE LOXIVELEUCEL | ChEMBL registry synonym — accepted as the source's own label CHEMBL6068448 ↗ |
| Known as | Sitocabnagene loxiveluecel | ChEMBL registry synonym — accepted as the source's own label CHEMBL6068448 ↗ |
| Known as | Sitocabtagene loxiveleucel | ChEMBL registry synonym — accepted as the source's own label CHEMBL6068448 ↗ |
| Known as | TAK-007 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06377228 ↗ |
| Route | Intravenous | “TAK-007 intravenous injection.” NCT05020015 ↗ |